Hikma has set out expected enhancements to its injectables business, following the completion of its recent agreement to acquire a bundle of US finished-dose assets from Xellia Pharmaceuticals following clearance under applicable US antitrust laws.
As a result of the deal – which saw Hikma agree to pay cash consideration of $135m, subject to customary adjustments, with additional contingent consideration of up to $50m payable upon achievement of certain regulatory and commercial milestones (see sidebar) –
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?